Incyte (INCY)
Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.
$127.00
After hours+0.09 (+0.07%)
At close$126.91(+1.81%)
Something off on this page? Send us feedback.
Next report
Oct 27, 26
in 35 days
EPS estimate
−$3.31
Revenue estimate
$1.47B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$1.43$1.16$1.57$2.26$1.80$1.81$3.09Pending
Estimate$1.57$1.01$1.39$1.66$1.90$1.34$2.15−$3.31
Surprise−8.9%+14.9%+12.9%+36.1%−5.3%+35.1%+43.7%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$1.18B$1.05B$1.22B$1.37B$1.51B$1.27B$1.67BPending
Estimate$1.00B$1.15B$1.26B$1.35B$1.35B$1.22B$1.50B$1.47B
Surprise+17.3%−8.7%−3.3%+0.9%+11.2%+4.7%+11.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $1.97 | — | — |
| Sep 2028 | $1.99 | — | — |
| Jun 2028 | $2.54 | — | — |
| Mar 2028 | $2.02 | — | — |
| Dec 2027 | $2.39 | — | — |
| Sep 2027 | $2.17 | — | — |
| Jun 2027 | $2.08 | — | — |
| Mar 2027 | $1.70 | — | — |
| Dec 2026 | $1.95 | — | — |
| Oct 2026 | −$3.31 | — | — |
| Jul 2026 | $2.15 | $3.09 | +43.7% |
| Apr 2026 | $1.34 | $1.81 | +35.1% |
| Feb 2026 | $1.90 | $1.80 | −5.3% |
| Oct 2025 | $1.66 | $2.26 | +36.1% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $1.97 | — | — | $1.63B | — | — | — |
| Sep 2028 | $1.99 | — | — | $1.61B | — | — | — |
| Jun 2028 | $2.54 | — | — | $1.67B | — | — | — |
| Mar 2028 | $2.02 | — | — | $1.49B | — | — | — |
| Dec 2027 | $2.39 | — | — | $1.70B | — | — | — |
| Sep 2027 | $2.17 | — | — | $1.59B | — | — | — |
| Jun 2027 | $2.08 | — | — | $1.54B | — | — | — |
| Mar 2027 | $1.70 | — | — | $1.38B | — | — | — |
| Dec 2026 | $1.95 | — | — | $1.53B | — | — | — |
| Oct 27, 2026 | −$3.31 | — | — | $1.47B | — | — | — |
| Jul 28, 2026 | $2.15 | $3.09 | +43.7% | $1.50B | $1.67B | +11.3% | +9.3% |
| Apr 28, 2026 | $1.34 | $1.81 | +35.1% | $1.22B | $1.27B | +4.7% | +2.1% |
| Feb 10, 2026 | $1.90 | $1.80 | −5.3% | $1.35B | $1.51B | +11.2% | −8.2% |
| Oct 28, 2025 | $1.66 | $2.26 | +36.1% | $1.35B | $1.37B | +0.9% | −1.5% |
| Jul 29, 2025 | |||||||
| Apr 29, 2025 | |||||||
| Feb 10, 2025 | |||||||
| Oct 29, 2024 | |||||||
| Jul 30, 2024 | |||||||
| Apr 30, 2024 | |||||||
| Feb 13, 2024 | |||||||
| Oct 31, 2023 | |||||||
| Aug 1, 2023 | |||||||
| May 2, 2023 | |||||||
| Feb 7, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 2, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 8, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 9, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Oct 29, 2019 | |||||||
| Jul 30, 2019 | |||||||
| Apr 30, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Oct 30, 2018 | |||||||
| Jul 31, 2018 | |||||||
| May 1, 2018 | |||||||
| Feb 15, 2018 | |||||||
| Oct 31, 2017 | |||||||
| Aug 1, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 14, 2017 | |||||||
| Nov 1, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 11, 2016 | |||||||
| Nov 3, 2015 | |||||||
| Aug 4, 2015 |